Seeking Alpha

Chelsea Therapeutics (CHTP) craters in spite of announcing positive preliminary results for...

Chelsea Therapeutics (CHTP) craters in spite of announcing positive preliminary results for Study 306B, a Phase III trial of Northera, a treatment for hypotension associated with Parkinson's Disease, saying the trial met its primary endpoint. The devil lies in the details however, as investors react to the results under the shadow of the FDA's earlier statement that the trial was unlikely to provide sufficient confirmatory evidence to support an NDA. Shares -22% AH.
From other sites
Comments (2)
  • wretchedturkey
    , contributor
    Comments (549) | Send Message
     
    Yikes! Just when I thought the end was near for CHTP... well the end may be near... just not the ending I was expecting!
    4 Dec 2012, 06:47 PM Reply Like
  • smokeyRose
    , contributor
    Comments (83) | Send Message
     
    Could the Reaction from investors be Wrong???
    We will Find Out! But maybe I don't let stock stick Around to find out!
    What a bummer! was such a good stock!
    5 Dec 2012, 12:07 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs